The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

A cancer vaccine generated using the cells left over after tumour removal surgery could help to keep patients from ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

New research has identified crucial components and mechanisms of the plant immune system, potentially helping to develop ...

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their ...

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.